An Account Representative’s Perspective: Five Key Things I Learned from Being Treated with PROKERA


As an account representative for Bio-Tissue, I look forward to visiting with doctors and staff and talking about the benefits of PROKERA. However, when I recently became a patient, I learned even more about the benefits of this biologic corneal bandage with cryopreserved amniotic membrane. This experience not only helped heal my ocular surface, but also provided valuable information I can pass on to doctors and staff.

"Why Intervene/5 D's” Reference Guide Now Available Online


To support doctors using PROKERA and inform others who may be interested in implementing Bio-Tissue’s biologic corneal bandage device in your practice, we recently made our "Why Intervene/5 D's" reference guide available to everyone online. This handy guide provides a quick reference to various indications where PROKERA provides clinical value, and we received such positive feedback to the print version that we decided to offer it electronically.

A Protocol for Use of PROKERA after Corneal Collagen Cross-Linking


With the Federal Drug Administration (FDA) approval of corneal collagen cross-linking (CXL) (Avedro, April 2016) for the treatment of progressive keratoconus, we can expect to see a high volume of these procedures being done by corneal specialists. Although the disease is considered rare, which according to the National Eye Institute (NEI) affects approximately one in every 2,000 Americans, the disease can lead to blindness if not treated. As we know, the surgical technique for performing CXL that is FDA-approved for use in the U.S. at this time is epithelium-off (epi-off, Dresden protocol).

Part 2: Amniotic Membrane Speeds Healing


In part one of a two-part series, Josh Johnston, OD discussed the paradigm shift in treating patients with dry eye. Here, he speaks to Primary Care Optometry News (PCON) about cryopreserved amniotic membrane and how it speeds healing.

In his last blog, Josh Johnston, OD, Georgia Eye Partners, spoke about the “Paradigm Shift in Treating Patients with Dry Eye” and how the introduction of new therapies allows doctors to provide better outcomes to patients and improve clinical outcomes. One of the therapies he spoke of is PROKERA with cryopreserved amniotic membrane, and its many benefits particularly for those patients with corneal involved dry eye.

Bringing Value & Affecting Change: A Representative's Role


You have all seen many industry representatives in your office and operating rooms, and I’m sure you have an opinion on what attributes define good and not-so-good salespeople. Having worked in eye care for a while now and being very passionate about what I do, I wanted to share my perspective on what I believe makes for a good representative. These attributes are what motivate me every day when I am out talking with many of you and your staff in your practices, and helping you reach your goals.

Successfully Treating a Chemical Corneal Burn


On the date of examination, this kind 25 year old Filipino gentleman, who is a UCONN adjunct professor, presented for an emergency in reference to a chemical burn injury while helping his student with an experiment containing trifluoroacetic acid. While attempting to salvage the work, the pressure built up in the tubing and exploded into his right eye. He immediately flushed the eye under a Morgan Lens for several minutes to mitigate the acidic response. Subsequently, the infirmary contacted our office to see him on the same day to assess the status of his eye. On arrival, he wore dark sunglasses, was in tremendous pain, had light sensitivity, and his eye was sealed shut.

The Dangers of Beauty Treatments


We all know using makeup, and particularly not removing it at night, can have a huge impact on eye health and lead to or worsen conditions such as blepharitis, Demodex and also dry eye. As such, it’s becoming increasingly important to discuss cosmetics and ocular hygiene with our patients. A recent case also highlights the dangers of beauty procedures, which are becoming increasingly popular, in this case eye lash tinting.

Treating Chronic Dry Eye: Why I Use CryoTek Cryopreserved Amniotic Membrane for These Patients


Dry eye is a multifactorial and progressive1 disease for which we use many treatments, but the Prokera® corneal bandage is the first and only biologically active treatment that directly targets the cornea. Prokera has been a game-changer in my practice. I use it not only for DEWS2 Level 3 and 4 patients, but also for those with Level 1 or 2 dry eye with corneal involvement, especially Sjögren’s patients, who are chronically uncomfortable and not responding to conventional therapies, even if there is a disconnect between their signs and symptoms.

Helping Patients Heal Faster While Maintaining Their Vision


A 58-year-old, wheelchair-bound female with a history of a CVA and unspecified neurologic disorder presented in my office complaining of severe blurry vision, severe pain, burning and a constant foreign body sensation of the left eye.

Her ocular history was significant for dense amblyopia in the right eye with a best corrected visual acuity of 20/400 and mild amblyopia of the left eye with a best corrected visual acuity of 20/60. She had been treated prior in the right eye with PROKERA® Slim when she presented initially months prior with similar symptoms in the right eye due to severe dry eye, secondary to an extremely low blink rate and lagophthalmos related to her neurologic disorder. Her signs and symptoms dramatically improved in the right eye. However, she did not feel comfortable placing PROKERA Slim in the left eye as she didn’t feel she would be able to safely go about her daily life with her left eye occluded and only 20/400 vision in her right eye.

ASCRS Success: Presentations Demonstrate Clinical Effectiveness of Regenerative Tissue Therapies


This year, ASCRS 2016 proved to be yet another successful conference. Many exciting papers, posters, videos, and distinguished speakers discussed our regenerative tissue therapies and ocular hygiene products for ocular surface diseases.